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Objective: In recent years, second‐line diabetes treatment with dipeptidyl
peptidase–4 inhibitors (DPP‐4i) increased with a corresponding decrease in
thiazolidinediones (TZDs). Using hospitalization for heart failure (HF) as a positive
control outcome, we explored the use of calendar time as an instrumental variable
(IV) and compared this approach to an active comparator new‐user study.
Methods: We identified DPP‐4i or TZD initiators after a 6‐month washout using
Medicare claims 2006–2013. The IV was defined as a binary variable comparing initi-
ators during October 2010 to December 2013 (postperiod) versus January 2008 to
May 2010 (preperiod). We examined IV strength and estimated risk differences
(RDs) for HF using Kaplan‐Meier curves, which were compared with propensity score
(PS)–weighted RD for DPP‐4i versus TZD.
Results: The IV compared 22 696 initiators (78% DPP‐4i) in the postperiod versus
20 283 initiators (38% DPP‐4i) in the preperiod, resulting in 40% compliance. The
active‐comparator (PS‐weighted) approach compared 26 198 DPP‐4i and 18 842
TZD initiators. Covariate balance across IV levels was slightly better than across treat-
ments (standardized difference, 3% vs 4.5%). The 1‐ and 2‐year local average treat-
ment effects of RD of HF per 100 patients in the “compliers” (95% confidence
intervals) were −0.62 (−0.99 to −0.25) and −0.88 (−1.46 to −0.25). Corresponding
PS‐weighted results were −0.20 (−0.33 to −0.05) and −0.18 (−0.30 to 0.03).
Conclusion: Both approaches indicated lesser risk of HF hospitalizations among
DPP‐4i vs TZD initiators. The magnitude of the estimated effects may differ due to
differences in the target populations and assumptions. Calendar time can be lever-
aged as an IV when market dynamics lead to profound changes in treatments.
KEYWORDS
calendar time, instrumental variables, pharmacoepidemiology1 | INTRODUCTION
Antihyperglycemic drugs are critical components of diabetes man-
agement, accounting for approximately 12% of diabetes costs.1-3blin, Ireland, in August 2016.
publication anywhere else.While several new antidiabetic drugs were introduced in the market
in the last decade, there also emerged safety concerns about
thiazolidinediones (TZDs), an established class of antihyperglycemic
drugs. In 2007, a meta‐analysis raised concerns over the cardiovas-
cular safety of rosiglitazone,4 after which it was pulled from the
European market,5 and in September 2010, the Food and Drug
KEY POINTS
• In recent years, second‐line treatment of patients with
type 2 diabetes with dipeptidyl peptidase–4 inhibitors
(DPP‐4i) increased with a corresponding decrease in
thiazolidinediones (TZDs). This crossover over a short
period may provide an opportunity to use calendar
time as an instrumental variable (IV). Using
hospitalization for heart failure (HF) as a positive
control outcome, we explored the use of calendar time
as an IV and compared this approach to an active
comparator new‐user study comparing DPP versusTZD.
• The binary IV defined based on drug initiation patterns
and the timing of safety signals compared initiators
during October 2010 to December 2013 (“postperiod”)
versus January 2008 to May 2010 (“preperiod”),
resulting in 40% compliance, which implies this is a
strong IV. Using Kaplan‐Meier methods, we estimated
the 1‐ and 2‐year risk differences for HF
hospitalization using 2 approaches: (1) IV approach
comparing postperiod versus preperiod and (2) active
comparator approach comparing DPP‐4i versus TZD
initiators using propensity score weighting.
• Both approaches including many sensitivity analyses
indicated lesser risk of HF hospitalizations among
DPP‐4i vs TZD initiators. The magnitude of the
estimated effects may differ due to differences in the
assumptions and target populations.
• Our results demonstrate that calendar time can be
leveraged as an IV when market dynamics lead to
profound changes in treatments over short periods.Administration (FDA) announced that its use would be severely
restricted in the United States.6 Also in 2010, the FDA released a
drug safety communication about the risk of bladder cancer with
pioglitazone7 and in 2011 approved updates to the pioglitazone
product labels to include this warning.8 According to a recent analy-
sis,3 the dipeptidyl peptidase–4 (DPP‐4i) class quickly gained signifi-
cant market share and was the most commonly prescribed new drug
class by 2012, but the use of TZDs decreased by 2012.
In observational studies, an active comparator balances the treat-
ment cohorts with respect to measured and unmeasured confounders,
thereby minimizing the potential for confounding by indication.9
Dipeptidyl peptidase–4 and TZD are both recommended as second‐
line antihyperglycemic drugs, with intermediate (DPP‐4i) to high
(TZD) efficacy, low risk of hypoglycemia,10 and comparable costs
before the generic pioglitazone was introduced in August 2012.11
The DPP‐4i and TZD drugs are therefore expected to be in therapeu-
tic equipoise in a population excluding anyone with clear contraindica-
tions.12 The increased use of DPP‐4i with a simultaneous decrease in
TZD use over a short period also provides an opportunity to use calen-
dar time as an instrumental variable (IV).13 Instrumental variable
methods serve as a natural experiment to compare drugs in settings
where substantial unmeasured confounding is expected.14-16 Common
IV in pharmacoepidemiology includes provider preference, calendar
time, distance to care, and geographic variation.17 Calendar time IV
arises from secular trends in medication use. Such trends can be a
result of effectiveness or safety releases, changes in physician prefer-
ences, formularies, or the introduction of new agents to the market.
Calendar time IV has been previously used in several settings including
studies of antidiabetic therapies on body mass index,18 colon cancer
treatments on survival,13 antivirals in HIV patients,19 hormone
replacement therapy, and myocardial infarction.20
Our study setting is unique as there exist both an active compar-
ator and also a potential calendar time IV arising from drug safety con-
cerns. Using hospitalization for heart failure (HF) as a positive control
outcome (increased HF risk with TZDs, not with DPP‐4i drugs
sitagliptin and alogliptin),21-23 we first explored the use of calendar
time as an IV. Next we compared this approach with an active compar-
ator new‐user study examining DPP‐4i versus TZD in a sample of
Medicare beneficiaries without prior HF.2 | METHODS
We used a 20% random sample of the 2007–2013 Medicare claims
data for this study. These data contain information about demo-
graphics, enrollment, inpatient, outpatient diagnoses, procedures, and
prescription drugs for each enrollee.24,25
From a population of Medicare beneficiaries aged >65 years, we
identified new users of DPP‐4i or TZD without the use of either drugs
in the prior 6 months. Index date was defined as the date of the first
prescription. Since TZDs are contraindicated in patients with existing
HF, 26 we excluded patients with diagnoses of HF and related condi-
tions (cardiomyopathy, arrhythmias, chronic kidney disease, edema,
and loop diuretic use). We required the patients to have at least
6 months of continuous part D enrollment and at least 12 monthsparts A and B enrollment preindex. To ensure that patients were actu-
ally started on the drugs, we restricted our cohorts to patients with a
second prescription for the same drug class dispensed within 6 months
after the index date.2.1 | Instrumental variable
An IV is an observed variable associated with the variation in exposure
similar to randomized assignment.16 To be valid, an IV must be (1)
associated with the treatment, (2) unrelated to patient characteristics,
and (3) related to the outcome only through its association with the
treatment. Additionally, to estimate the average treatment effect in
the “compliers,” the instrument should affect treatment deterministi-
cally in one direction (monotonicity assumption).16
We defined the IV as a binary variable (“postperiod” versus
“preperiod”) anchored around the time of the crossover of the drug
initiation curves (June to September 2010), which was also the time
when the FDA issued safety communications about TZDs. In our
study, compliers are patients initiating TZD before the crossover and
DPP‐4i after the crossover. We identified an “optimal” IV by evaluat-
ing the percentage of compliers (the strength of the instrument's
effect on the received treatment).13 We examined the instrument in
relation to IV assumptions using the proportion of compliers, partial
F tests, measured covariates, and expert knowledge. In IV analyses,
the approach of examining covariate balance by only looking at the
standardized absolute mean differences (SAMDs) ignores the scaling
factor and can be potentially misleading while evaluating confounding
bias. Therefore, we evaluated covariate balance with the “actual treat-
ment initiated” approach and IV approach by using both the SAMDs
and bias components taking into account scaling of the IV as proposed
by Jackson et al.27 The binary measure of calendar time was decided
before examining the effect estimates.
2.2 | Outcome
Heart failure hospitalization was defined as an inpatient claim with
International Classification of Diseases, Ninth Revision, code 428.xx
in the primary position.28 Thiazolidinediones are known to increase
HF risk,21 and while saxagliptin is suspected to be associated with
an increased HF risk, other DPP‐4i drugs (constituting >80% of our
cohort, Table S1) are not.22,23,29 Heart failure hospitalization is there-
fore a positive control outcome in our study enabling the comparison
of the analysis “comparing the actual treatments initiated” versus the
“IV analysis comparing levels of the calendar time instrument.” Using
an intent‐to‐treat (ITT) approach, patients were followed from the sec-
ond prescription date until the earliest of HF hospitalization, death,
end of enrollment, or 2 years after the index date.
2.3 | Confounding control and analysis
We used weighted Kaplan‐Meier methods to estimate the 1‐ and 2‐
year risk differences (RDs) for HF hospitalization comparing (a) actual
treatment received (DPP‐4i vs TZD) and (b) IV approach (postperiod
versus preperiod). Under the “treatment received” approach, we first
estimated the propensity score (PS) for DPP‐4i versus TZD30 using
logistic regression with baseline variables measured preinitiation. The
year of initiation was not included in PS estimation because it was a
suspected instrument strongly associated with the exposure but not
with the outcome, and conditioning on such a variable could bias theFIGURE 1 Initiation of dipeptidyl peptidase 4 inhibitors (DPP‐4i) vers
definition of the instrumental variable (IV): Medicare claims data 2007–20results and increase variance. 31 We then assigned inverse probability
of treatment weights (IPTW) of 1/PS to DPP‐4i and 1/(1 − PS) toTZD
and stabilized both groups by marginal prevalence of the treatment
actually received.32 Using IPTW‐weighted Kaplan‐Meier curves, we
estimated the RDs for HF hospitalization with treatment received as
the strata variable and with a robust variance estimator.33
The effect of the IV levels on HF hospitalization was observed by
the IV estimates of 1‐ and 2‐year RDs scaled by IV strength to estimate
the local average treatment effect among compliers. In a secondary
analysis, we generated covariate‐adjusted IV estimates of the RD using
weighted Kaplan‐Meier methods analogous to the IPTW‐weighted
method and scaled this by IV strength.
These methods are appreciably different—IV estimates apply to
the marginal patients while IPTW PS methods apply to the whole
study population. Propensity score models used the full study popula-
tion, and we performed sensitivity analyses in the reduced IV cohort
to evaluate selection differences that may have been introduced
based on IV exclusions.13 Next, we performed a sensitivity analysis
restricting the study cohort to patients who initiated treatment
between July 2007 and December 2011, with follow‐up through
December 2013. This approach excluded anyone who initiated
therapy during or after January 2012, whowould not have the potential
for a 2‐year follow‐up before the end of the study). We also performed
additional analyses with different definitions of the instrument to
assess the effects of potential time trends in the outcome and effects
of scaling by compliance percentage (Figures S2 and S3).3 | RESULTS
The preferred treatments changed dramatically over the study period
(Figure 1). The optimal binary IV compared the postperiod (October
2010 to December 2013, N = 22 696) with the preperiod (January
2008 to May 2010, N = 20 283). This definition excludes patients
during June 2010 to September 2010 where the curves intersect.
With this IV definition, the DPP‐4i treatment rates were 78% and
38% in the postperiod and preperiod, respectively, and the strengthus thiazolidinediones (TZD) across calendar time and the resultant
13 [Colour figure can be viewed at wileyonlinelibrary.com]
of the IV (% compliers) was 40%. The partial F statistic assessing the
association between the treatment and calendar time was 4596.7.
While the covariates were well balanced across DPP‐4i versus
TZD, the balance was slightly better across the levels of the IV as illus-
trated by the average SAMD of 4.5% vs 3.0%, respectively (Table 1).
This indicates that the IV is independent of the measured risk factors
of the outcome and potentially also unmeasured covariates. We also
calculated the bias components to compare the covariate balance
for the 2 analytic approaches (Table 1, last 2 columns). The bias
component for the IV approach was relatively higher than the bias
component with the “actual treatment initiated” approach for key
variables like diabetic neuropathy, retinopathy, and baseline use of
metformin and sulfonylureas, but the magnitude of the SAMD with
both approaches was <10%.
In the full population comparing DPP‐4i versus TZD, the crude
incidence rate per 100 000 was 563 in DPP‐4i and 676 in TZD initia-
tors (Table 2). The 1‐ and 2‐year risks for HF hospitalization were 0.5%
and 1.2% for DPP‐4i and 0.7% and 1.3% for TZD, respectively (Figure
S1). In the reduced IV population, crude incidence rate per
100 000 person‐years was 509 in the postperiod and 695 in the
preperiod. The 1‐ and 2‐year risks for HF hospitalization were 0.4%
and 1.1% in the postperiod and 0.7% and 1.4% in the preperiod,
respectively.
The crude RD was similar to the IPTW‐weighted RD (Figure 2)
obtained by comparing DPP‐4i versus TZD, expected because of the
balance of baseline covariates achieved by the use of an active com-
parator. The IV estimates of the RDs scaled by IV strength were con-
sistent overall with the IPTW‐weighted RDs indicating a protective
effect with the DPP‐4i but relatively less precise and farther from
the null. The 2‐year RD per 100 patients obtained using the IV analysis
scaled by IV strength was −0.62 (−0.99 to −0.25) indicating that of the
1000 compliant patients treated with DPP‐4i, 6 fewer patients would
be expected to have an HF hospitalization during the first year relative
to those with TZD. Covariate‐adjusted IV estimates of the RD were
similar (Figure 2, Table S2).
Sensitivity analyses in a population restricted to patients initiating
on or before December 2011, analyses using IPTW weighting in the
reduced IV population (Table S3), and analyses using different defini-
tions of the IV to assess the effects of scaling and potential outcome
time trends yielded similar results (Figures S2 and S3).4 | DISCUSSION
This study compared the performance of 2 methods to estimate the
effect of DPP‐4i versus TZD initiation on the risk of HF hospitaliza-
tion, a positive control outcome. The first method used an active com-
parator design using IPTW weighting, while the second method
compared posttime versus pretime using calendar time as an IV and
found lesser risk of HF hospitalization with DPP‐4i.
The absolute 1‐year risks of HF hospitalization in the sitagliptin
and pioglitazone arms (together accounting for approximately 85%
of our population; Table S1) were approximately 1% and 2%, respec-
tively, in previous randomized trials.21,23 These trials found no
increased risk with sitagliptin and 0.5% increased risk withpioglitazone relative to placebo at 1 year; however, there are no data
directly comparing DPP‐4i with TZD. In our study, the claims‐based
HF definition had a high specificity but a low sensitivity,28 which led
to an underestimation of absolute HF risks and therefore also RDs
for both the IPTW and IV methods. While we could have chosen to
estimate relative risks, we chose to estimate RD because we were
interested in an absolute measure of effect, which is more interpret-
able and relevant in our setting. Moreover, different IV methods used
to derive relative measures require different additional assumptions
like a special type of noncompliance (noncompliers are only those
who do not take the treatment when assigned to the treatment) or
about the homogeneity of risks within the levels of the treatment.16,34
While the RDs from both approaches generally agreed, the IV
estimates were less precise, and the magnitudes of the RDs differed
because the 2 methods apply to different populations and are based
on different assumptions. The IPTW‐weighted RD is the average
treatment effect in the entire population, while the scaled RD from
the IV analysis is the average treatment effect in the 40% compliers
from the reduced IV population. Scaling the RD involves dividing the
RD by the IV strength of 40%. The weaker the instrument, the larger
the scaled estimate gets relative to the unscaled RD, potentially mag-
nifying any biases present in the unscaled RD.16 In a sensitivity analy-
sis (Figure S2), we defined the instrument by a cut‐point (before and
after July 2010), which made this a weaker instrument (IV strength,
25%), and the scaled 1‐year RD was −0.73 (−1.74 to 0.27), which
has a larger magnitude than the main analysis, but in the same direc-
tion. In another analysis (Figure S3), we compared the periods with
maximum separation (December 2011 to December 2012 versus June
2008 to June 2009). This definition led to a stronger IV (strength,
50%), and as expected, the scaled 1‐year RD was closer to the
unscaled estimate (−0.45; CI, −0.92 to 0.05). Thus, scaling could
explain some of the differences in magnitude of the IV estimates of
RDs compared with the IPTW‐weighed RDs seen in the main analysis.
We compared the characteristics of the compliers with that of the full
population and found that the populations were generally similar with
minor differences insufficient to explain our results (Table S4).
It is also important to critically assess IV assumptions. While we
empirically observed that calendar time strongly affected the treatment
initiation, the assumption of calendar time being unrelated to the out-
come through other mechanisms could be potentially violated due to
time trends in the outcome. However, no strong trends in HF hospital-
izations were empirically observed in the population excluded from our
study due to previousHF or other criteria (between 3.1% to 4.6% of the
initiators were excluded each year during the study period due to a pre-
viousHF hospitalization). The literature reports reduction in the rates of
HF hospitalization amongMedicare beneficiaries due to several reasons
including decreased smoking and increasing outpatient management.35
The Hospital Readmissions Reduction Program started in late 2012
requires Centers for Medicare & Medicaid Services (CMS) to penalize
hospitals with excess readmissions for certain conditions including HF,
which may somewhat explain the decreasing trend in HF hospitaliza-
tions, but since this only affects a small proportion of our study period,
this is not expected to meaningfully affect our results.36
Assuming a decreasing trend in the rates of HF hospitalization










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TABLE 2 Number of new users, heart failure hospitalizations, time on treatment, total person time, and incidence for comparisons of levels of








Incidence (per 100 000
Person‐ years)
Post vs Prea Post 22 696 146 1.36 (0.64‐2.00) 28 661 509.40
Pre 20 283 255 2.00 (2.00‐2.00) 36 682 695.16
DPP‐4i vs TZD DPP‐4i 26 198 210 2.00 (1.79‐2.00) 37 252 563.73
TZD 18 841 215 2.00 (1.68‐2.00) 31 791 676.29
Abbreviations: DPP‐4i, dipeptidyl peptidase–4 inhibitors; TZD, thiazolidinedione.
aPost, October 2010 to December 2013; pre, January 2008 to May 2010.
bUnder the first treatment carried forward/intent‐to‐treat analysis, patients were followed up from the second prescription of the initiated drug to earliest
of the outcome occurrence, death, or 2 years after initiation without accounting for treatment changes during follow‐up.
FIGURE 2 Comparison of risk differences
(RDs) for heart failure hospitalization:
Medicare claims data 2007–2013. Estimates
of risk difference are based on risks per 100
patients estimated from Kaplan‐Meier survival
curves. The instrumental variable (IV)
estimator is scaled by a compliance
percentage of 40%. Adjusted estimates
account for the variables presented in Table 1.
IPTW, inverse probability of treatment
weight; PS, propensity score [Colour figure
can be viewed at wileyonlinelibrary.com]in the direction of favoring DPP‐4i relative toTZD. An increasing trend
on the other hand is expected to bias the results against DPP‐4i in
favor of TZD. To minimize the effect of time trends, we conducted a
sensitivity analysis using a dichotomous cut‐point of calendar time
(before and after July 2010) and estimated 1‐year RD comparing the
12 months after versus before the cut‐point. As described above,
the RD observed was only slightly larger than the RD in the base‐caseanalysis but pointed in the same direction. The assumption that the IV
is unrelated to patient characteristics is also not empirically verifiable,
but it is upheld by the improvement in the covariate balance across
post versus pre compared with the balance across DPP‐4i versus
TZD as indicated by the SAMD and bias components for the 2
approaches. The bias components for the IV approach were higher
than the “actual treatment initiated” approach for key variables like
diabetic neuropathy, retinopathy, baseline use of metformin, and
sulfonylureas, indicating that not adjusting for these variables in
the IV analyses would result in more bias than not adjusting them in
the conventional PS‐weighted active comparator analysis. However,
the bias component method only gives an idea about the relative bias
but not absolute bias.27 In this study, the magnitude of the SAMD for
both approaches was <10% for these variables, and our adjusted and
unadjusted IV estimates are only slightly different indicating no signif-
icant concern for confounding by these variables in our main analysis.
The assumption of monotonicity also seems to be reasonable in this
study as it is unlikely that a patient would initiate DPP‐4i in the
preperiod while an identical patient would initiate TZD in the
postperiod in spite of the warnings about TZD. Any impact of the
generic pioglitazone in August 2012 on this study would be in the last
year only and therefore unlikely to be a serious concern. There were
no events that would preclude DPP‐4i initiator in the preperiod from
receiving DPP‐4i in the postperiod, especially given the reports
suggesting a lack of serious adverse events with these agents in the
past few years.37,38
Some additional caveats should be considered. Our ITT analysis
approach could lead to exposure misclassification as it does not
take into account treatment changes. However, the IV estimator
is a measure of the association between the treatment assignment
(i.e., treatment intent) and the outcome. Therefore, using a conceptu-
ally uniform ITT approach for the IPTW‐weighted analysis comparing
DPP‐4i versus TZD initiation would facilitate direct comparison of
the RDs obtained by the 2 methods. Finally, it could be argued that
confounding exists in the DPP‐4i versus TZD comparison by unmea-
sured factors like body mass index or smoking. However, body mass
index is not likely to affect the choice of initiation of DPP‐4i versus
TZD in these patients, and chronic obstructive pulmonary disease
was available as a proxy for smoking, which reduces the concern of
confounding by these variables.39
A key strength of our study was the identification of a calendar
time IV that strongly affected the exposure, driven by the dynamics
of the antihyperglycemic drug market. Time trends in the exposure
also offer other study design options like secular trend analyses. Com-
pared with a secular trend analysis that is more useful in forecasting
future outcomes and generating hypotheses, using calendar time as
a binary IV in this study enabled clear visualization of the measured
patient characteristics by levels of the IV and enabled conditioning
on any remaining imbalances while at the same time also checking if
there is a trend in the outcome. These features make the IV method
more intuitive while drawing conclusions about comparative perfor-
mance of the treatments of interest.
It is often conservatively suggested to avoid IV methods when the
assumptions are likely to be violated because relatively minor viola-
tions of the assumptions may lead to large biases.14 This can be partic-
ularly problematic when there is no valid comparison analytic method.
In our setting, the use of a positive control outcome and observing
consistent results with both IV and IPTW methods imply that both
may be equally valid and supplement each other at the very least.
Our results indicate that calendar time can be leveraged as a strong
IV in settings where market dynamics lead to profound changes in
preferred treatments.FUNDING
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